Holen Sie sich die Stockscreener-App
0.655
0.85%
-0.0056
Handel nachbörslich:
.67
0.015
+2.29%
Alx Oncology Holdings Inc Aktie (ALXO) Neueste Nachrichten
Alx Oncology Faces Nasdaq Delisting Risk Amid Stock Price Slump - TipRanks
ALX Oncology shares fall 1.51% after-hours following Q2 2025 earnings call and investor presentation. - AInvest
Peninsula biotech company sets two clinical trials to revive its cancer-fighting fortunesSan Francisco Business Times - The Business Journals
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Q2 2025 Earnings Call Transcript - Insider Monkey
ALX Oncology Q2 2025 Earnings Call Transcript - MarketBeat
ALX Oncology shares rise 6.34% premarket after positive Q2 2025 results and clinical trial updates. - AInvest
ALX Oncology Holdings Inc Reports Promising Trial Results and Pipeline Progress - AInvest
ALX Oncology Holdings Inc (ALXO) Q2 2025 Earnings Call Highlights: Promising Trial Results and ... - Yahoo Finance
ALX Oncology Holdings Inc. Moves Into Overbought Range Analysts CautiousWeekly Watchlist of High Movers Released - 선데이타임즈
ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
ALX Oncology Advances Cancer Therapy Pipeline - TipRanks
ALX Oncology Holdings Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:ALXO) - Seeking Alpha
Transcript : ALX Oncology Holdings Inc., Q2 2025 Earnings Call, Aug 12, 2025 - MarketScreener
ALX Oncology : Investor Presentation (d1ea01) - MarketScreener
ALX Oncology Holdings Earnings Preview: Analyst Estimates and Past Performance - AInvest
Earnings call transcript: ALS Oncology Q2 2025 reports EPS miss By Investing.com - Investing.com Canada
ALX Oncology Holdings Inc reports results for the quarter ended June 30Earnings Summary - TradingView
ALX Oncology Appoints Dr. Curran to Board - TipRanks
ALX Oncology Reports Second Quarter 2025 Financial Results and P - GuruFocus
Q2 2025 ALX Oncology Holdings Inc Earnings Call Transcript - GuruFocus
ALX Oncology Q2 2025 slides: biomarker strategy shows promise as cash runway extends - Investing.com Canada
ALX Oncology Reports Significant Advances in Evorpacept Trials and Updates Corporate Strategy - Quiver Quantitative
ALX Oncology Holdings Inc. Provides Clinical Trail Update - MarketScreener
Using RSI to spot recovery in ALX Oncology Holdings Inc.Weekly Growth Portfolio Performance Summary - Newser
Does ALX Oncology Holdings Inc. align with a passive investing strategyQuick Win Portfolio Stocks - thegnnews.com
ALX Oncology Holdings Inc. stock trend forecastSector Rotation Outlook With Historical Summary - Newser
Visual trend scoring systems applied to ALX Oncology Holdings Inc.Steady Return Plan Based on Data Analysis - Newser
Why ALX Oncology Holdings Inc. stock attracts strong analyst attentionTechnical Trend Forecast for Investors - Newser
Is ALX Oncology Holdings Inc. stock poised for growthFree Daily Growth Stock Pick Reports - Newser
Is ALX Oncology Holdings Inc. stock bottoming outBreakout Stock Opportunities with Low Drawdown - Newser
Will ALX Oncology Holdings Inc. see short term momentumPredictive AI Engine for Smart Investing - Newser
What indicators show strength in ALX Oncology Holdings Inc.Proven Trading System with Consistent Gains - Newser
How Interest Rate Changes Impact ALX Oncology Holdings Inc. Stock PerformancePortfolio Building Plan and Summary Guide - Newser
Can machine learning forecast ALX Oncology Holdings Inc. recoveryFree Investment Plan With Growth Optimization - Newser
Gastric Cancer Market on Growth Trajectory: Novel Therapies Drive Momentum Through 2034 | DelveInsight - GlobeNewswire Inc.
Developing predictive dashboards with ALX Oncology Holdings Inc. dataSwing Gain Strategy with Entry Forecast - Newser
How ALX Oncology Holdings Inc. stock performs during market volatilityFree Target Return Focused Trade Insights - Newser
Why ALX Oncology Holdings Inc. is moving todayPrice Action Trading with Volume Confirmation - Newser
Chart overlay techniques for tracking ALX Oncology Holdings Inc.Watchlist Generator for Smart Money Signals - Newser
Tools to monitor ALX Oncology Holdings Inc. recovery probabilityHigh Accuracy Trade Setup Identification - Newser
ALX Oncology Holdings Inc expected to post a loss of 45 cents a shareEarnings Preview - TradingView
Earnings Preview: ALX Oncology to Report Financial Results Post-market on August 12 - 富途牛牛
How to read the order book for ALX Oncology Holdings Inc.Smart Stock Forecast Using AI Algorithms - Newser
Custom watchlist performance reports with ANNAWSmart Trade Forecast Based on Neural Logic - Newser
ALX Oncology: Assessing Q2 2025 Earnings and Pipeline Catalysts for Immuno-Oncology Growth - AInvest
ALX Oncology Holdings Inc. to Report Second Quarter 2025 Financial Results and Business Update on August 12, 2025 - Quiver Quantitative
ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025 - GlobeNewswire
ALX Oncology Sets Date for Q2 2025 Earnings: Key Business Updates Expected from Cancer Drug Pipeline - Stock Titan
ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025 | ALXO Stock News - GuruFocus
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
0.11%
1.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):